The Experts below are selected from a list of 306 Experts worldwide ranked by ideXlab platform
Richard E Hautmann - One of the best experts on this subject based on the ideXlab platform.
-
Upper Urinary Tract recurrence after radical cystectomy for bladder cancer who is at risk
The Journal of Urology, 2009Co-Authors: Bjoern G Volkmer, Thomas J Schnoeller, Rainer Kuefer, Kilian M Gust, F Finter, Richard E HautmannAbstract:Purpose: Patients who underwent radical cystectomy for bladder cancer are at risk for Upper Urinary Tract recurrence. We identified subgroups of patients at increased risk for Upper Urinary Tract recurrence.Materials and Methods: All 1,420 patients who underwent radical cystectomy for bladder cancer at our center between January 1986 and October 2008 were included in the study. Negative frozen sections of the ureteral margins were obtained from all patients. Data analysis included preoperative tumor history, pathological findings of the cystectomy specimen and complete followup. Survival was calculated using the Kaplan-Meier method.Results: Until October 2008, 25 cases of Upper Urinary Tract recurrence were observed. The overall rate of Upper Urinary Tract recurrence at 5, 10 and 15 years was 2.4%, 3.9% and 4.9%, respectively. Of the patients 3 had superficial tumors of the renal pelvis and 22 had invasive Upper Tract transitional cell carcinoma. Upper Urinary Tract recurrence did not develop in any patie...
S. Alan Mcneill - One of the best experts on this subject based on the ideXlab platform.
-
A comparison of the pathology of transitional cell carcinoma of the bladder and Upper Urinary Tract
BJU international, 2005Co-Authors: Grant D. Stewart, Simon V. Bariol, Ken Grigor, David A. Tolley, S. Alan McneillAbstract:OBJECTIVE To clarify the histopathological patterns of Upper and lower Urinary Tract transitional cell carcinomas (TCCs), as previous reports suggest that Upper Urinary Tract TCCs have a greater tendency towards high-grade disease than bladder TCCs, of which most are low-grade and low-stage tumours. PATIENTS AND METHODS All patients presenting with TCC of bladder or Upper Urinary Tract between February 1991 and December 2001 at one institution were identified. Further patient information was obtained from the hospital database and case-note review. RESULTS In all, 164 patients with Upper Urinary Tract TCC and 2197 with bladder TCC were identified. There was a correlation between grade and stage of both Upper Urinary Tract and bladder TCCs. 35% of the Upper Tract TCCs were classified as grade 2 and 44% as grade 3, while for bladder TCCs, 31% of lesions were classified as grade 2 and 35% as grade 3 (P = 0.003). Of the Upper Urinary Tract lesions 33% were stage pT2–T4, compared with only 20% of bladder TCCs (P = 0.001). CONCLUSIONS Upper Urinary Tract TCC is a higher grade and stage disease than bladder cancer, a finding that emphasizes the need for aggressive treatment of Upper Urinary Tract TCC. If endourological management of Upper Urinary Tract TCC is considered, histopathological determination of tumour grade before treatment is essential.
See-tong Pang - One of the best experts on this subject based on the ideXlab platform.
-
The outcome of patients on dialysis with Upper Urinary Tract transitional cell carcinoma.
The Journal of urology, 2006Co-Authors: Phei-lang Chang, Chih-shou Chen, Cheng-keng Chuang, Hsu-huei Weng, See-tong PangAbstract:Purpose: Transitional cell carcinoma is the most common Upper Urinary Tract cancer in Taiwanese patients on dialysis. It is a unique finding compared with Western countries. Unfortunately, the long-term outcomes of patients with Upper Urinary Tract transitional cell carcinoma on dialysis are largely unknown. This study presents clinical outcome of patients on dialysis with Upper Urinary Tract transitional cell carcinoma.Materials and Methods: We retrospectively reviewed the medical records of all patients with Upper Urinary Tract transitional cell carcinoma who had end stage renal disease and underwent dialysis. Traditional prognostic factors including age, sex, tumor grade, stage and tumor location were analyzed with respect to disease recurrence and survival.Results: A total of 73 patients were included in this study. The major complaints were painless gross hematuria and urethral bloody discharge. Disease relapsed in 40 (54.8%) patients at average time of 15 months (2 to 92). Univariate analysis failed...
Paul H. Noh - One of the best experts on this subject based on the ideXlab platform.
-
Infant Robotic Bilateral Upper Urinary Tract Surgery
Korean journal of urology, 2014Co-Authors: Danesh Bansal, Christopher M. Bean, Brian A. Vanderbrink, Paul H. NohAbstract:We describe a case of robot-assisted laparoscopic bilateral Upper Urinary Tract surgery in a 4-month-old infant for complex bilateral Upper Urinary Tract duplication anomalies.
Zhen Chen - One of the best experts on this subject based on the ideXlab platform.
-
The detection of PAX8 in human Upper Urinary Tract urothelial carcinoma.
International journal of clinical and experimental pathology, 2018Co-Authors: Hua Xiang, Na Zhao, Zhen ChenAbstract:Upper Urinary Tract urothelial carcinomas (UUT-UCs) are defined as malignant neoplasms of the urothelium from the Upper Urinary Tract, including renal calyces, the renal pelvis and the distal ureter. The natural attributes of UUT-UCs differ from those of bladder cancer. The aim of the present study was to investigate PAX8 expression in the normal urothelium and in urothelial carcinomas (UCs) of the Upper Urinary Tract. Immunohistochemistry was conducted in 35 cases of renal pelvic and 30 cases of ureteral papillary UCs and the adjacent normal urothelium respectively. PAX8 mRNA expression was evaluated by RT-PCR in a different set of normal urothelial mucosa of the Urinary Tract and UUT-UCs. In immunohistochemical studies, the positive rates of PAX8 staining in UCs of the renal pelvis and ureter were 17% and 6.6% respectively, presenting focally positive in most cases, while the positive rates in the adjacent normal epithelia of the pelvis and ureter were 100% and 93% respectively. PAX8 mRNA was detected in all of the tumors and adjacent normal urothelial mucosa specimens of the Upper Urinary Tract. 4 types of PAX8 isoforms, PAX8a, PAX8b, PAX8c and PAX8e, were detected in UUT-UCs in this study. As in bladder cancer, PAX8 expression was highly heterogeneous in terms of the splicing mRNA isoforms, with the different isoforms differentially expressed in the UUT-UCs. Among the 4 types of PAX8 isoforms, the PAX8e isoform was found in almost all UUT-UCs tumor tissues, but the PAX8d isoform was not detected in UUT-UCs that were different from the transcriptional splicing patterns of PAX8 in bladder cancer reported in the literature. In addition, the above 4 types of PAX8 splicing isoforms were simultaneously detected in almost all of the normal mucosal epithelia of the Upper Urinary Tract, which was very different from that of bladder mucosa. Further studies are suggested to reveal whether or not the differences in natural attributes between UCs of the Upper and lower Urinary Tracts are related to their PAX8 transcriptional splicing patterns.
